Structure-Based Survey of the Binding Modes of BACE1 Inhibitors
- PMID: 30540177
- DOI: 10.1021/acschemneuro.8b00420
Structure-Based Survey of the Binding Modes of BACE1 Inhibitors
Abstract
BACE1 is a key aspartic protease that cleaves the amyloid precursor protein to generate of the amyloid peptide that is believed to be responsible for the Alzheimer's disease amyloid cascade. It is thus recognized as a promising therapeutic target for Alzheimer's disease treatment, and large efforts have been made in the discovery of novel BACE1 inhibitors. This Review presents a systematic mining of BACE1 inhibitors based on 354 crystal structures of the BACE1 catalytic domain in complex with ligands in the Protein Data Bank. A thorough exploration on the frequency as well as the patterns of residue-ligand interactions enables us to subdivide the ligand binding pocket into 10 subsites and then identify favorable substructures of ligands for each subsite. In addition, it is found that the assembly of subsites with an 8-like shape is responsible to bind all inhibitors and four major ligand binding modes are revealed. Thus, such a systematic survey deepens our understanding of the structural requirements for establishment of BACE1-ligand interactions that determine the affinity of a ligand to BACE1, which is pivotal for structure-based lead optimization and design of novel inhibitors.
Keywords: Alzheimer’s disease; BACE1; inhibitor; ligand binding mode; subsite; substructure.
Similar articles
-
Computational analysis of BACE1-ligand complex crystal structures and linear discriminant analysis for identification of BACE1 inhibitors with anti P-glycoprotein binding property.J Biomol Struct Dyn. 2018 Jan;36(1):262-276. doi: 10.1080/07391102.2016.1276477. Epub 2017 Jan 12. J Biomol Struct Dyn. 2018. PMID: 28081663
-
Discovery of furo[2,3-d][1,3]thiazinamines as beta amyloid cleaving enzyme-1 (BACE1) inhibitors.Bioorg Med Chem Lett. 2016 Dec 1;26(23):5729-5731. doi: 10.1016/j.bmcl.2016.10.055. Epub 2016 Oct 20. Bioorg Med Chem Lett. 2016. PMID: 27816517
-
Conformational dynamics of cathepsin D and binding to a small-molecule BACE1 inhibitor.J Comput Chem. 2017 Jun 5;38(15):1260-1269. doi: 10.1002/jcc.24719. Epub 2017 Apr 2. J Comput Chem. 2017. PMID: 28370344 Free PMC article.
-
Fragment-based designing for the generation of novel leads against BACE1.Cent Nerv Syst Agents Med Chem. 2015;15(1):52-64. doi: 10.2174/1871524915666150127122546. Cent Nerv Syst Agents Med Chem. 2015. PMID: 25625854 Review.
-
BACE1 as a therapeutic target in Alzheimer's disease: rationale and current status.Drugs Aging. 2013 Oct;30(10):755-64. doi: 10.1007/s40266-013-0099-3. Drugs Aging. 2013. PMID: 23842796 Review.
Cited by
-
Protective effects of BACE1 inhibitory ligand molecules against amyloid beta-induced synaptic and mitochondrial toxicities in Alzheimer's disease.Hum Mol Genet. 2020 Jan 1;29(1):49-69. doi: 10.1093/hmg/ddz227. Hum Mol Genet. 2020. PMID: 31595293 Free PMC article.
-
Allostery Inhibition of BACE1 by Psychotic and Meroterpenoid Drugs in Alzheimer's Disease Therapy.Molecules. 2022 Jul 8;27(14):4372. doi: 10.3390/molecules27144372. Molecules. 2022. PMID: 35889246 Free PMC article.
-
Development of Activity Rules and Chemical Fragment Design for In Silico Discovery of AChE and BACE1 Dual Inhibitors against Alzheimer's Disease.Molecules. 2023 Apr 20;28(8):3588. doi: 10.3390/molecules28083588. Molecules. 2023. PMID: 37110831 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical